BarbriSFCourseDetails
  1. keyboard_arrow_leftBack

Course Details

Course Information
  • smart_display Format

    On-Demand

  • signal_cellular_alt Difficulty Level

  • work Practice Area

    Real Property - Transactions

Date & Time
  • event Date

    Wednesday, February 19, 2020

  • schedule Time

    1:00 p.m. ET./10:00 a.m. PT

  • timer Program Length

    90 minutes

Credit Information

  • This 90-minute webinar is eligible in most states for 1.5 CLE credits.

$347.00
CLE
ALL

This CLE course will provide real estate counsel with a review of the statutory framework and the latest developments relating to the Interstate Land Sales Full Disclosure Act (ILSFDA). The panel will discuss recent amendments, including a partial exemption for the sale of condo units, how the Consumer Financial Protection Bureau (CFPB) and courts are addressing ILSFDA, and best practices to ensure compliance.

Faculty

Judyann M. Lee
Partner
McMillan Metro, PC

Ms. Lee’s real estate practice focuses primarily on issues surrounding common interest projects, including homeowners associations, commercial, residential and mixed-use condominiums, cooperatives, and timeshare resorts. She frequently represents associations after their transition to homeowner management. Ms. Lee leverages that practical operational knowledge to help clients in the formation of these associations.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Joey E. Lubinski
Partner
MDH Law Group, LLC

Mr. Lubinski is a member of the firm’s Real Estate, Development and Construction team. His varied transactional real estate practice runs the life cycle of commercial development, with particular focus on real estate finance matters. Mr. Lubinski has extensive experience in the acquisition, disposition and financing of commercial properties.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio

Description

Developers of residential property should be aware that there is a federal statute that prohibits the sale across state lines of subdivision lots or units unless they are registered with the CFPB or are exempt from registration. ILSFDA presents complex compliance issues for developers and their counsel. They include the applicability of ILSFDA to specific developments and exemption from ILSFDA registration requirements in several different development scenarios.

An amendment to ILSFDA to partially exempt condominium developments took effect on Mar. 25, 2015. In the four years since some applications of the exemption are clear, but several key issues remain unresolved or fraught with ambiguity. Moreover, the amendment did not grandfather in condo developments that were in the sales process before the effective date.

Court interpretations of the Act are inconsistent, and developers must continuously navigate potential legal land mines within ILSFDA. Counsel to developers must ensure properties are properly registered under ILSFDA or are exempt from the Act.

Listen as our authoritative panel of attorneys provides their unique perspectives, overview, and analysis of current ILSFDA regulations, guidelines, and procedures, including the new partial exemption for condo developments, ILSFDA litigation developments, and CFPB ILSFDA-related enforcement activity.

Outline

  1. ISLFDA statutory and regulatory framework
  2. 2015 amendment partially exempting condo developments
  3. The CFPB 2016 electronic filing initiative
  4. Legal issues with registration statements
  5. Exemptions and drafting pointers
  6. Enforcement activity
  7. Recent private litigation developments

Benefits

The panel will review these and other key issues:

  • When is registration required under ILSFDA, and what are the continuing compliance requirements?
  • How does the CFPB identify targets for investigation?
  • What issues have not been resolved or remain ambiguous in the recent condo exemption amendment?
  • How are courts addressing ILSFDA cases?
  • What are the compliance options, alternatives, strategies, and pitfalls for developers under ILSFDA?